These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8060249)

  • 41. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
    Polkinghorne KR; McMahon LP; Becker GJ
    Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.
    Reeves JH; Cumming AR; Gallagher L; O'Brien JL; Santamaria JD
    Crit Care Med; 1999 Oct; 27(10):2224-8. PubMed ID: 10548211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan.
    Suzuki T; Ota K; Naganuma S; Koshikawa S; Hirasawa Y; Nakagawa S; Otsubo O; Akizawa T
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():46-54. PubMed ID: 1962904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis.
    Von Bonsdorff M; Stiekema J; Harjanne A; Alapiessa U
    Int J Artif Organs; 1990 Feb; 13(2):103-8. PubMed ID: 2347652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of anticoagulation on blood membrane interactions during hemodialysis.
    Hofbauer R; Moser D; Frass M; Oberbauer R; Kaye AD; Wagner O; Kapiotis S; Druml W
    Kidney Int; 1999 Oct; 56(4):1578-83. PubMed ID: 10504511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of citrate-enriched bicarbonate based dialysate on anticoagulation and dialyzer reuse in maintenance hemodialysis patients.
    Rocha AD; Padua VC; Oliveira E; Guimaraes MM; Lugon JR; Strogoff de Matos JP
    Hemodial Int; 2014 Apr; 18(2):467-72. PubMed ID: 24261328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of oral anticoagulation on clotting during hemodialysis.
    Ziai F; Benesch T; Kodras K; Neumann I; Dimopoulos-Xicki L; Haas M
    Kidney Int; 2005 Aug; 68(2):862-6. PubMed ID: 16014067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dialyzer reuse--part II: advantages and disadvantages.
    Twardowski ZJ
    Semin Dial; 2006; 19(3):217-26. PubMed ID: 16689973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does an alteration of dialyzer design and geometry affect biocompatibility parameters?
    Opatrný K; Krouzzecký A; Polanská K; Mares J; Tomsů M; Bowry SK; Vienken J
    Hemodial Int; 2006 Apr; 10(2):201-8. PubMed ID: 16623675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dialyzer performance over prolonged reuse.
    Gagnon RF; Kaye M
    Clin Nephrol; 1985 Jul; 24(1):21-7. PubMed ID: 3926361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Appropriate dosage of unfraction heparin and low molecular weight heparin in hemodialysis patients].
    Xiao Q; Sun XF; Zhang D; Ma ZF; Wu MG; Wang H; Chen XM
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):187-91. PubMed ID: 20356555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane.
    Ljungberg B; Jacobson SH; Lins LE; Pejler G
    Clin Nephrol; 1992 Aug; 38(2):97-100. PubMed ID: 1325310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of re-utilization of cuprophan capillary dialysers with different liquids on their biocompatibility and effectiveness of elimination].
    Orłowski A; Szepietowski T
    Polim Med; 1992; 22(1-2):59-72. PubMed ID: 1461837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Use of urea kinetic modeling for evaluating the efficacy of reusing capillary dialyzers].
    Drozdz M; Sułowicz W; Drozdz D; Kopeć J
    Przegl Lek; 1996; 53(5):406-11. PubMed ID: 8754402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Water permeability of high-flux dialyzer membranes after Renalin reprocessing.
    Labib ME; Murawski J; Tabani Y; Wolff SH; Zydney AL; Funderburk FR; Huang Z; Kapoian T; Sherman RA
    Kidney Int; 2007 Jun; 71(11):1177-80. PubMed ID: 17377505
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparison of the hemodialysis adequacy conducted based on low-flux polysulfone dialyzers and high-flux helixone dialyzers].
    Sobaszek-Pitas M; Kopeć J; Krzanowski M; Sułowicz W
    Przegl Lek; 2014; 71(7):384-8. PubMed ID: 25338334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparative study of heparin and a very low molecular-weight heparin in hemodialysis in chronic renal insufficiency].
    Hory B; Cachoux A; Saunier F; Kieffer Y; Laroze M; Henriet MT; Toulemonde F; Bayrou B; Perol C
    Presse Med; 1987 May; 16(19):955-8. PubMed ID: 2954145
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimization of heparin anticoagulation for hemodialysis.
    Davenport A
    Hemodial Int; 2011 Oct; 15 Suppl 1():S43-8. PubMed ID: 22093600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.